BI's Phase II Drug Could Be The First Second-Wave Protease Inhibitor For HCV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BOSTON - Competition is heating up in the hepatitis C space, not to be first to market with a small-molecule therapy but to produce a second-generation drug with a better dosing regimen and fewer side-effects than either of the two current frontrunners: Vertex Pharmaceuticals' telaprevir and Schering-Plough's boceprevir